Virtual oncology care platform Reimagine Care and The Center for Cancer and Blood Disorders have partnered to support patients receiving advanced cell therapies. 

The Advanced Therapy Management (ATM) programme provides a model designed to support outpatient post-infusion monitoring and management of CAR-T and other advanced oncology therapies.  

 The expansion builds on the organisations’ existing collaboration focused on extending oncology care beyond the clinic. Across that partnership, Reimagine Care says it has supported more than 6,100 unique patients, generating more than 220,000 patient interactions between Reimagine Care’s virtual assistant Remi and its clinicians in the Virtual Care Center (VCC).   

More than 90% of encounters are independently managed by Reimagine Care without requiring escalation to The Center’s care team. When escalation is needed, Reimagine Care’s average response time is less than 10 minutes — a critical capability for CAR-T patients where toxicities like CRS can progress from mild symptoms to life-threatening complications in hours. 

The collaboration also has driven a 55% reduction in avoidable emergency department visits for patients during their first six months of treatment. 

“CAR-T patients require an extraordinary level of coordination and vigilance, especially in the first several weeks after treatment,” said Barry Russo, CEO of The Center for Cancer and Blood Disorders.  

 “This collaboration allows us to extend our reach beyond the walls of the clinic and maintain close visibility into how patients are doing between visits. That’s increasingly important as advanced therapies become more common in community oncology.”  

“Advanced therapies like CAR-T are changing what’s possible in cancer care, but they also require a fundamentally different level of monitoring and coordination,” said Reimagine Care CEO Dan Nardi.

“These patients can deteriorate quickly, and toxicity doesn’t operate on clinic hours. Our work with The Center is about creating the clinical infrastructure to safely extend these therapies into outpatient settings while giving patients and providers continuous visibility and support.”